aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.17−0.00 (-1.32%)
Close on Oct 19, 2026Market cap $16.84MP/E –Yield –
aTYR PHARMA free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
aTYR PHARMA's free cash flow for the twelve months ending Jun 30, 2026 was -$54.82M. For fiscal 2025 it was -$62.06M. The highest annual figure on record is -$15.50M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.06M | – |
| FY2024 | Dec 31, 2024 | -$69.18M | – |
| FY2023 | Dec 31, 2023 | -$37.44M | – |
| FY2022 | Dec 31, 2022 | -$43.53M | – |
| FY2021 | Dec 31, 2021 | -$33.27M | – |
| FY2020 | Dec 31, 2020 | -$15.50M | – |
| FY2019 | Dec 31, 2019 | -$20.09M | – |
| FY2018 | Dec 31, 2018 | -$31.66M | – |
| FY2017 | Dec 31, 2017 | -$43.68M | – |
| FY2016 | Dec 31, 2016 | -$53.46M | – |
| FY2015 | Dec 31, 2015 | -$37.46M | – |
| FY2014 | Dec 31, 2014 | -$23.07M | – |
| FY2013 | Dec 31, 2013 | -$17.96M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.46M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.40M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.84M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.10M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.53M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.79M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.84M | -408.9% |
| Q4 FY2020 | Dec 31, 2020 | -$5.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.57M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.42M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.89M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.82M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.03M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.50M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.08M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.47M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.34M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.15M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.74M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.75M | – |
See a number that looks wrong?